Julie Tordo,Claire O’Leary,André S L M Antunes,Nuria Palomar,Patrick Aldrin-Kirk,Mark Basche,Antonette Bennett,Zelpha D’Souza,Hélène Gleitz,Annie Godwin,Rebecca J Holley,Helen Parker,Ai Yin Liao,Paul Rouse,Amir Saam Youshani,Larbi Dridi,Carla Martins,Thierry Levade,Kevin B Stacey,Daniel M Davis,Adam Dyer,Nathalie Clément,Tomas Björklund,Robin R Ali,Mavis Agbandje-McKenna,Ahad A Rahim,Alexey Pshezhetsky,Simon N Waddington,R Michael Linden,Brian W Bigger,Els Henckaerts

Abstract:Recombinant adeno-associated viruses (AAVs) are popular in vivo gene transfer vehicles. However, vector doses needed to achieve therapeutic effect are high and some target tissues in the central nervous system remain difficult to transduce. Gene therapy trials using AAV for the treatment of neurological disorders have seldom led to demonstrated clinical efficacy. Important contributing factors are low transduction rates and inefficient distribution of the vector. To overcome these hurdles, a variety of capsid engineering methods have been utilized to generate capsids with improved transduction properties. Here we describe an alternative approach to capsid engineering, which draws on the natural evolution of the virus and aims to yield capsids that are better suited to infect human tissues. We generated an AAV capsid to include amino acids that are conserved among natural AAV2 isolates and tested its biodistribution properties in mice and rats. Intriguingly, this novel variant, AAV-TT, demonstrates strong neurotropism in rodents and displays significantly improved distribution throughout the central nervous system as compared to AAV2. Additionally, sub-retinal injections in mice revealed markedly enhanced transduction of photoreceptor cells when compared to AAV2. Importantly, AAV-TT exceeds the distribution abilities of benchmark neurotropic serotypes AAV9 and AAVrh10 in the central nervous system of mice, and is the only virus, when administered at low dose, that is able to correct the neurological phenotype in a mouse model of mucopolysaccharidosis IIIC, a transmembrane enzyme lysosomal storage disease, which requires delivery to every cell for biochemical correction. These data represent unprecedented correction of a lysosomal transmembrane enzyme deficiency in mice and suggest that AAV-TT-based gene therapies may be suitable for treatment of human neurological diseases such as mucopolysaccharidosis IIIC, which is characterized by global neuropathology.

AAV-delivered suppressor tRNA overcomes a nonsense mutation in mice

Developing AAV-delivered nonsense suppressor tRNAs for neurological disorders

Utilizing AAV-mediated LEAPER 2.0 for Programmable RNA Editing in Non-Human Primates and Nonsense Mutation Correction in Humanized Hurler Syndrome Mice.

Translation velocity determines the efficacy of engineered suppressor tRNAs on pathogenic nonsense mutations

Restoration of dystrophin expression in mice by suppressing a nonsense mutation through the incorporation of unnatural amino acids

Therapeutic Nonsense Suppression Modalities: From Small Molecules to Nucleic Acid-Based Approaches

Anticodon Engineered Transfer RNAs (ACE-tRNAs) are a Platform Technology for Suppressing Nonsense Mutations

Mini-dCas13X–mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy

mRNA-specific readthrough of nonsense codons by antisense oligonucleotides (R-ASOs)

Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Mosaic CRISPR-stop enables rapid phenotyping of nonsense mutations in essential genes

Optimization of Anticodon Edited Transfer RNAs (ACE-tRNAs) Function in Translation for Suppression of Nonsense Mutations

Engineered IscB-ωRNA system with improved base editing efficiency for disease correction via single AAV delivery in mice

Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS

Rescue of auditory function by a single administration of AAV-TMPRSS3 gene therapy in aged mice of human recessive deafness DFNB8

In Vivo Genome Editing Partially Restores Alpha1-Antitrypsin in a Murine Model of AAT Deficiency

AAV-based delivery of RNAi targeting Ataxin-2 improves survival, strength, and pathology in mouse models of rapidly and slowly progressive sporadic ALS

A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency

Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor

Rescue of spinal muscular atrophy mouse models with AAV9-Exon-specific U1 snRNA